SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Midterm election results and the prospect of a Democratic sweep dominate discussion, with traders blaming perceived regulatory and AI-spending risks for QQQs sharp volatility while others argue the outcome was priced in and the selloff is an overreaction. Strong AMD and Super Micro results also fueled optimism about AI-related tech and a possible rebound.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention around midterm election results and expectations of Democratic gains, with traders connecting a potential loss of Republican control to political risk for Trump Media. The conversation is largely bearish, though some users argue the results are routine midterm losses or anticipate a rebound.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs quarterly earnings beat and stronger outlook, driven by surging AI data-center demand, sparked a sharp rally and renewed optimism about growth into 2027. Traders remain divided, with concerns about valuation, weaker cash flow and dependence on data-center spending weighing against the bullish outlook, while broader market and election worries contributed to volatile trading.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros quarterly results and raised full-year outlook, driven by strong AI-server demand, are the main focus. Many traders call the results a major beat and see the shares as undervalued, while others question thin margins, cash flow, and lingering management credibility concerns that may be weighing on the stocks muted response.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL chatter centers on sharp swings in semiconductor stocks amid concerns about an AI trade pullback, election uncertainty, and selling in chip names such as AMD, Intel, and Marvell. Traders remain divided between expecting a rebound on strong chip demand and earnings, and warning that persistent selling and leveraged-ETF decay could deepen losses.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Midterm-election uncertainty is driving volatility in Nvidia and the broader AI trade, with traders debating whether a Democratic sweep could weigh on data-center spending and AI regulation or whether the risk is already priced in. AMDs strong results are also fueling optimism that AI-chip demand remains resilient, supporting a semiconductor rebound.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

A letter from 28 HOPE-3 investigators urging FDA approval of Capricors deramiocel and defending the trial data has intensified discussion ahead of the FDA decision. Many traders see the letter as strengthening the approval case and fueling the rally, while others point to the adverse advisory-committee review and uncertainty over the FDAs interpretation of the data; claims of leaks or short covering remain speculation.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a sharp, sector-wide selloff in AI infrastructure and neocloud stocks, as traders debate whether the AI buildouts debt, funding needs and uncertain profitability justify lower valuations. Bulls call the decline an oversold, market-driven pullback and are buying dips, while bears warn that financing risks and bubble concerns could drive further losses; the latest bounce has not settled the debate.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas pullback is being tied by traders to midterm-election uncertainty, with speculation that Democratic gains could bring congressional scrutiny of Elon Musk and complicate the proposed TeslaSpaceX combination; others see merger speculation or the political outcome as potential support. The debate is compounded by criticism that Teslas valuation is hard to justify given concerns about earnings and sales, alongside short-term options volatility.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Ciphers Q3 revenue miss has intensified concerns about its early transition from bitcoin mining to AI data-center leasing, financing needs and execution. Bulls point to initial HPC lease revenue and expanded long-term contracts, while bears question whether those prospects offset near-term losses; the sharp rebound has also fueled oversold-bounce and short-squeeze speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HUTCHMED (China) Reports H1 2026 Results: Full Earnings Call Transcript

HUTCHMED (China) (NASDAQ:HCM) released quarterly financial results and hosted an earnings call on Thursday. Read the complete transcript below.
This transcript is brought to you by Benzinga APIs. For real-time access toread more...

AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success

AstraZeneca halts a phase III NSCLC study for volrustomig after data show that the regimen is unlikely to meet key survival goals, while other lung cancer trials shine.

Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating

Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating...

HUTCHMED (NASDAQ:HCM) Hits New 52-Week Low  - What's Next?

HUTCHMED (NASDAQ:HCM) Hits New 12-Month Low - What's Next...

HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference

HUTCHMED (NASDAQ:HCM) executives highlighted 2025 financial results, commercial momentum for its marketed oncology portfolio, and upcoming clinical and regulatory catalysts during a presentation at...

HUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's Why

HUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's Why...

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Rating of "Hold" by Analysts

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM - Get Free Report) has been given an average rating of "Hold" by the six ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold...

Short Interest in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Decreases By 13.7%

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM - Get Free Report) saw a large decrease in short interest during the month of March. As of March 13th, there was short interest totaling 278,317 shares, a decrease of 13.7% from the February 26th total of 322,619 shares. Currently, 0.2% of the...

HUTCHMED (NASDAQ:HCM) Shares Gap Up   - Time to Buy?

HUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy...

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of "Hold" from Brokerages

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM - Get Free Report) has been given a consensus rating of "Hold" by the six ratings firms that are presently covering the stock, Marketbeat Ratings...

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

HUTCHMED (China) Limited - ADR

Hutchmed Stock Hits Over One-Month High After China Accepts Kidney Cancer NDA Filed With Partner Innovent Biologics

Equity

Neutral Sentiment

Shares of Hutchmed (China) hit their highest levels in over a month after the company announced along with Innovent Biologics that their NDA for a kidney cancer treatment had been accepted by China's drug regulator.At the close on Wednesday, Hutchmed shares rose 4.1% to $15.3, with an additional 0.5% gain to $15.38 in after-hours trading.The China National Medical Products Administration (NMPA) accepted for review the NDA for fruquintinib combined with sintilimab as a treatment for patients with advanced renal cell carcinoma who did not respond to tyrosine kinase inhibitor therapy, according to a joint company statement.Results of the FRUSICA-2 trial showed the drug met its primary progression-free survival goal and also improved secondary measures such as objective response rate and duration of response.“Submitting this NDA...marks an important step in our efforts to address this unmet need,” said Michael Shi, head of R&amp;D and chief medical officer at Hutchmed.Hui Zhou, senior vice president at Innovent, said the filing represents the tenth indication for sintilimab, calling it a milestone in lifecycle management.The combination therapy received conditional approval from the NMPA in December 2024 for patients with advanced mismatch repair proficient endometrial cancer.Fruquintinib is approved in China under the brand Elunate and is marketed globally as Fruzaqla by Takeda.&nbsp;Sintilimab, co-developed by Innovent and Eli Lilly, is approved for multiple indications and included in China’s national reimbursement list.On Stocktwits, retail sentiment was ‘neutral’ amid ‘high’ message volume.The stock has risen 1.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

China's drug regulator accepted the companies’ NDA for a combination therapy targeting advanced renal cell carcinoma.

Hutchison China MediTech

Republicans keep both chambers

Republicans keep the House, lose the Senate

Republicans keep the Senate, lose the House

Democrats win both chambers

Stocktwits

Stocktwits Polls

$HCM 🏥 

HUTCHMED (China) Limited announced that the US FDA granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia, making it eligible for development incentives including seven years of US market exclusivity upon approval. 

Curated for market relevance

Rayvio | Market News Filter

$HCM 🏥 

HUTCHMED (China) Limited announced positive SANOVO Phase III trial results showing ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% overall and 55% in high MET overexpression first-line EGFR-mutated lung cancer patients. 

Timely market event

Feed

News

Sentiment

Earnings

Fundamentals

Info

HCM Hutchison China MediTech

Fundamentals

Latest HCM News